small-cell lung cancer 8 years experience of a single multidisciplinary team小细胞肺癌8年经验的一个多学科小组.pdf

Hindawi Publishing Corporation Journal of Oncology Volume 2008, Article ID 150760, 6 pages doi:10.1155/2008/150760 Clinical Study Small-Cell Lung Cancer: 8 Years Experience of a Single Multidisciplinary Team Loaie M. El-Helw,1 Trevor K. Rogers,1 and Matthew Q. F. Hatton2 1 Chest Department and Lung Cancer Clinic, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster Royal Infirmary, Doncaster DN2 5LT, UK 2 Department of Clinical Oncology, Weston Park Hospital, Sheffi eld S10 2SJ, UK Correspondence should be addressed to Loaie M. El-Helw, loaieelhelw@ Received 2 June 2008; Accepted 24 September 2008 Recommended by Nasser K. Altorki Aims . We have audited the changes in treatment practice for small-cell lung cancer (SCLC) presented to a single multidisciplinary team (MDT) at Doncaster and Bassetlaw Hospitals between January 1998 and December 2005. Materials and Methods. The MDT database was used to identify all patients with SCLC. Anonymised demographic, treatment, and outcome details were extracted from the database supplemented by patient records. Results. 235 patients were identified. 112 (48%) had limited disease at presentation. Chemotherapy was the initial treatment for 195 patients, 77% of whom had a documented radiological response with a complete response in 24%. Chemotherapy regimes evolved during the study period with the increasing use of platinum-based chemotherapy. Anthracycline-based chemotherapy was most used before 2004 and was given to 57% of all patients. 42% received consolidation thoracic radiotherapy and 24% prophylactic cranial irradiation. The median and 2-year survival were 8 months and 18%, respectively, for patients with limited disease and 5 months and 5%, respectively, for extensive disease. Conclusion.